CMT2C for clinicians: a summary for each specialty
CMT2C is rare, so most clinicians meet it once or twice in a career. This page gathers, for each specialty, what the published sources say: what the condition is, what is usually checked, the known cautions, and the papers behind each point. None of it is my own words: a patient brought the experts’ words together, as a starting point, not a guideline. Choose your specialty below to see only that section, with its papers and why each one is relevant.
CMT2C is an autosomal dominant axonal neuropathy caused by gain-of-function variants in TRPV4, a calcium-permeable ion channel [10]. Unlike most forms of CMT, it often involves the vocal folds and the diaphragm, and it can affect hearing, the skeleton and the bladder [6]. Severity varies widely, even within one family, and cannot be predicted from the variant [6]. No treatment yet changes its course [5]; care is surveillance and symptom management by a multidisciplinary team, with checks once a year [6].
Where this comes from. I live with CMT2C and I am not a clinician. Nothing here is my own medical opinion: every point is the published experts’ words, cited beside it, mostly the GeneReviews chapter by McCray, Schindler, Hoover-Fong and Sumner [6] and the 2025 TRPV4 registry paper in Brain[3], brought together in one place so it is easier to digest and to check at its source. It is a consolidation, not a guideline. Where the site draws on literature about neuromuscular disease in general rather than CMT2C, it says so.
A one-page summary for any clinician
The key point: in CMT2C the weakness is not only in the feet and hands; the voice box and the breathing muscles are often involved, and the sources caution against oxygen alone or CPAP for weak breathing muscles.
What it is
Autosomal dominant axonal CMT caused by gain-of-function variants in TRPV4[10]. Also written up as HMSN 2C, TRPV4 neuropathy, scapuloperoneal SMA (SPSMA) and congenital distal SMA (CDSMA), which are now treated as one overlapping spectrum [6].
Rare: Orphanet lists a prevalence under 1 in 1,000,000 [1].TRPV4 explains an estimated 1 to 3.5% of CMT2 and related motor neuropathies [6].
Onset from birth to after 80, with two peaks: 54% of registry participants had symptoms within the first 2 years of life, and a smaller peak came at 34 to 48 years [3][6].
Nerve conduction studies show reduced motor amplitudes with normal velocities; EMG shows mainly chronic neurogenic changes [6].
What is different from typical CMT
Vocal fold weakness is a hallmark: diagnosed in 55% of registry participants, and in 85% of those who had actually been examined by an ENT specialist [3]. Hoarseness 45%, inspiratory stridor 40% [3].
Diaphragm weakness: 55% short of breath, 23% on BiPAP, more than 10% have needed ventilatory support or a tracheostomy [3]. In severe forms, respiratory complications can shorten life [6].
Proximal weakness: 40% had proximal leg weakness on examination, against 4% in a CMT1A comparison group [3]. Shoulder girdle (scapular) weakness is part of the picture [6].
Skeleton: foot deformities 73%, scoliosis 39 to 64% depending on the data source, clubfoot 45%, arthrogryposis 33%, hip dysplasia 18% [3]. Some variants also cause a skeletal dysplasia [6].
Hearing loss in 27%, bladder symptoms in up to 45% [3]. Sensory symptoms are often absent (68% reported none) although vibration sense is reduced on examination in 84% [3].
Recommended surveillance (GeneReviews)
After diagnosis: video laryngoscopy, pulmonary function tests and dynamic chest radiographs, a sleep study, a hearing assessment and skeletal radiographs [6]. Then, once a year: voice box, breathing, sleep, hearing, feet and skeleton, with weight and height at each visit [6].
Cautions
Oxygen alone can be dangerous when breathing muscles are weak: guidance for other neuromuscular conditions warns that it can mask or worsen hypercapnia without ventilatory support [153]. The sources advise measuring carbon dioxide, not only saturation [126].
CPAP does not treat neuromuscular hypoventilation[307]. Weak breathing muscles need ventilation: bilevel support with a wide pressure gap and a backup rate, or a home ventilator [307][308]. Some references still write “BiPAP or CPAP” together [6].
Anesthesia: vocal fold weakness and diaphragm weakness both matter. Reviews of anesthesia in neuromuscular disease call for a careful preoperative assessment, close monitoring and ventilatory support ready afterward [290].
Neurotoxic drugs: the CMTA's evidence-based list names vincristine (severe, sometimes irreversible worsening) and paclitaxel [35]. A 2023 systematic review found no convincing evidence against other drugs and stressed that people with CMT should not be denied effective treatments [36].
Upper respiratory infections cause vocal fold swelling and worsen airway obstruction; GeneReviews also advises avoiding obesity and diabetes [6].
Where to send people
The CMTA keeps a directory of CMT Centers of Excellence [85] and of clinicians with CMT experience [128]. Two natural history studies recruit people with TRPV4 variants: the Johns Hopkins TRPV4 study, NCT05600764 (United States and Canada) [101], and INC 6601, the Inherited Neuropathy Consortium's study for all CMT types, at 21 sites in five countries [52].Details below.
Neurology
The key point: in a patient with axonal CMT, vocal cord paralysis, scapular weakness, a skeletal dysplasia or hearing loss are the published clues that point to TRPV4 testing [18].
What the literature describes
An axonal motor-predominant neuropathy: reduced motor amplitudes with normal conduction velocities, and chronic neurogenic changes on EMG [6]. Many patients report no sensory symptoms, yet vibration sense is reduced on examination in 84% [3].
Weakness that is not length-dependent: proximal leg weakness in 40% (4% in CMT1A) and scapular weakness, alongside the usual distal pattern [3][6]. Wheelchair use was 19% against 1% in CMT1A [3].
Wide variability, including within one family, from arthrogryposis at birth to an asymptomatic 70-year-old carrier [6]. Age predicts severity less well than in CMT2A or CMTX1 [3].
Age of onset has two peaks, early childhood and the mid-thirties to late forties [3].
What the sources recommend
Genetic confirmation: sequence analysis detects essentially all pathogenic TRPV4variants [6]. Variants of uncertain significance are common, and a 2025 study showed that separating pathogenic from benign TRPV4 variants takes combined clinical, structural and cellular evidence [22]. The site's TRPV4 variants page lists the well-documented ones.
The baseline work-up GeneReviews recommends: video laryngoscopy, pulmonary function tests with dynamic chest radiographs, a sleep study, audiology and skeletal radiographs, then yearly review [6]. Standard CMT care focused on the feet and hands is not enough for this subtype [6].
Coordination: GeneReviews describes care as multidisciplinary, across neurology, rehabilitation medicine, orthopedics, audiology, laryngology, pulmonology, and physical and occupational therapy [6]. From the patient side, the neuromuscular neurologist is usually the one who coordinates.
Research: both natural history studies need participants, and the registry authors call for outcome measures that capture non-length-dependent weakness, vocal fold weakness and respiratory involvement, which standard CMT scales miss [3].How to refer.
Cautions
Vincristine and paclitaxel are the two drugs with evidence-backed potential for harm in CMT [35][36].
In a progressive condition with no disease-modifying treatment [5], the first TRPV4-targeted drug, STAR-0871 (previously ABS-0871), has completed a Phase 1a study in healthy volunteers, and its developer plans a trial in people with CMT2C in 2027 [318][319]. Patients may ask about it; the Trials and research page keeps the status current.
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: The registry that gives the bulbar, skeletal and proximal figures quoted in this section.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
For this specialty: The US cohort behind the clinical clues for TRPV4 testing: vocal cord paralysis, scapular weakness, skeletal dysplasia or hearing loss.
Relevance to CMT2C: Describes people with TRPV4-related CMT2C, including voice, breathing and hearing problems and variation within a family, and estimates how often TRPV4 explains CMT2 in a USA clinic cohort.
For this specialty: Reduced penetrance in one family, from a severely affected child to a relative with no findings at 70.
Relevance to CMT2C: A detailed study of a family with a TRPV4 ankyrin-region change (Arg269Cys) that directly addresses penetrance and variability, which matter to people with CMT2C and their relatives.
Berth et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: How pathogenic and benign TRPV4 variants were told apart with combined clinical, structural and cellular evidence.
Relevance to CMT2C: It directly addresses how to tell disease-causing from harmless TRPV4 variants in neuropathy, which matters for anyone given an uncertain TRPV4 result, but most of the work is in lab cells rather than patients.
Fawcett et al. · 2012 · Journal of neurology, neurosurgery, and psychiatry
Full paperPeer-reviewed journal
For this specialty: TRPV4 screened in a large series of inherited neuropathies, with the features that went with a positive result.
Relevance to CMT2C: It measures how often TRPV4 changes cause axonal CMT and motor neuropathy and shows that many rare TRPV4 variants are harmless, which matters for anyone given a TRPV4 result, though no confirmed CMT2C cases were found.
All 271 papers the site has read are on Papers explained, each with what was read (full text, detailed notes or abstract only) and what its evidence rests on.
Pulmonology and sleep medicine
The key point: in the neuromuscular literature, hypoventilation from a weak diaphragm is treated with ventilation (bilevel or a ventilator); CPAP and oxygen alone are cautioned against [307][153].
What the literature describes
Diaphragm weakness is part of the disease [6]. In the registry, 55% were short of breath, 23% used BiPAP, 10% used CPAP, and more than 10% had needed ventilatory support or a tracheostomy [3].
Vocal fold weakness in most patients [3], so inspiratory stridor (40%) and upper airway obstruction coexist with the muscle weakness [3][6]. Orthopnea and sleep apnea can occur [6].
These points come from a specialist's review of respiratory management in neuromuscular disease in general [288]; none has been studied in CMT2C specifically.
Vital capacity sitting and supine. A fall of more than 7.5% on lying down points to diaphragm weakness, often before upright values change [288]. GeneReviews lists dynamic chest radiographs alongside pulmonary function tests [6].
Nocturnal carbon dioxide, not only oximetry: standard sleep studies are built for apnea and can score hypoventilation as apneas [288].
Cough peak flow; about 160 liters a minute is the minimum for an effective cough [288]. For a weak cough: air stacking and mechanical insufflation-exsufflation, set up while the patient is well [288].
If ventilation is needed: bilevel support with a wide gap between inspiratory and expiratory pressures, a backup rate, or volume-assured modes [307][311]. The 2023 CHEST guideline recommends non-invasive ventilation for chronic respiratory failure in neuromuscular disease [308].
Yearly review of breathing and sleep, as GeneReviews recommends [6].
Cautions
“Continuous positive-airway pressure (CPAP) is not adequate to treat hypoventilation that occurs with NMD” [307]. Some patients are still told to fail CPAP first [312]. CPAP has a place only for obstructive sleep apnea confirmed by testing in a patient whose breathing muscles are strong [288].
Oxygen without ventilatory support can mask or worsen hypercapnia [153].
Colds are the usual trigger for respiratory crises, when a weak cough cannot clear secretions [288]. A plan for infections, agreed in advance, is something patients often ask for.
For this specialty: The review behind the three tests in this section: supine vital capacity, nocturnal carbon dioxide and cough peak flow. About neuromuscular disease in general, not CMT2C.
For this specialty: Bilevel settings, backup rates and volume-assured modes in neuromuscular disease, and the sentence on CPAP and hypoventilation quoted here.
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: The registry figures for breathlessness, BiPAP use and ventilatory support in TRPV4 disease.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
For this specialty: CMT2C families in which two people developed respiratory failure.
Relevance to CMT2C: It is directly about CMT2C families, with detailed clinical descriptions of variable onset, breathing failure and relatives with signs but no symptoms.
For this specialty: The chapter that still lists BiPAP and CPAP together, which a patient may have read.
Relevance to CMT2C: A clinical overview written specifically about TRPV4 neuromuscular disease, with CMT2C as a named core phenotype.
The patient-facing version of this page is Breathing and voice, with a printable handout on morning headaches.
ENT, laryngology and speech therapy
The key point: vocal fold paresis is a hallmark of TRPV4 disease [6], and it is usually missed until someone looks: 85% of registry participants examined by an ENT specialist had it, against 55% diagnosed overall [3].
What the literature describes
Vocal fold weakness or paralysis, hoarseness (45%) and inspiratory stridor (40%) [3]. In the first description of the disease, it was the combination of distal weakness with vocal cord and diaphragm paresis that defined it [6].
Across all CMT types, a 2001 review found only 11 published cases of vocal fold paresis and said many had probably been missed [313]. In TRPV4 disease it is the rule rather than the exception [3].
Within one family the same variant ranged from no vocal fold problem to a permanent tracheotomy (Chen et al., 2010).
What the sources recommend
Video laryngoscopy at diagnosis and a yearly voice box review, as GeneReviews recommends [6].
Management as listed by GeneReviews: speech therapy, laryngeal surgery when needed, vocal fold lateralization to widen the airway in selected patients, and tracheostomy for some [6].
Swallowing: the registry grouped voice, swallowing and breathing as bulbar manifestations [3]; patients value a swallowing assessment when they report choking or a weak cough.
Hearing is often affected in the same patients (27%) [3]; see Audiology.
Cautions
Upper respiratory infections cause vocal fold swelling and can worsen airway obstruction [6].
Before any procedure under sedation or anesthesia, the airway and the diaphragm both need planning; see Anesthesiology.
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: The 85% figure among those examined by an ENT specialist, against 55% diagnosed overall.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
McEntagart · 2012 · Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Abstract onlyReview, peer-reviewed journal
For this specialty: A review of the TRPV4 axonal neuropathy spectrum, vocal cord weakness included.
Relevance to CMT2C: It is a review focused directly on TRPV4 neuropathy, the condition that includes CMT2C, covering its features, inheritance and penetrance.
For this specialty: The review across all CMT types that found only 11 published cases and suggested many had been missed.
Anesthesiology and surgical teams
The key point: vocal fold and diaphragm weakness are both common and often undiagnosed; reviews of anesthesia in neuromuscular disease recommend a careful preoperative assessment and ventilatory support ready afterward [290].
What the literature describes
Vocal fold paresis in most patients, often undiagnosed [3], and diaphragm weakness that may show only when supine [288].
Patients who cannot lie flat comfortably, and some who already use nocturnal bilevel ventilation (23% in the registry) [3].
Orthopedic surgery is common in this group: 49% had had foot surgery [3], and spinal fusion is considered for scoliosis with pain or respiratory compromise [6].
What the sources recommend
The site has no CMT2C-specific anesthesia literature. These points are what reviews of anesthesia in neuromuscular disease, collected by the patient charity Breathe with MD, consistently say [290].
A careful preoperative respiratory assessment, including vital capacity supine as well as sitting [288], and knowledge of the patient's laryngoscopy findings.
Close monitoring during and after the procedure, including carbon dioxide [126].
Noninvasive ventilation available for recovery, and the patient's own bilevel settings if they use one [290][307].
Many patients carry a summary of their breathing results and know their own stridor and swallowing history.
Cautions
Supplemental oxygen without ventilatory support can mask or worsen hypercapnia in neuromuscular weakness [153].
CPAP does not treat hypoventilation from weak muscles [307].
Postoperative respiratory infections carry extra risk when the cough is weak [288].
One 2026 case report describes severe noninfectious wound dehiscence after cavovarus reconstruction in a child with TRPV4-associated CMT; a single case cannot show a general healing problem, but the authors raise the question (Elhaddad et al., 2026).
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: The rates of ventilatory support and tracheostomy in TRPV4 disease.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
For this specialty: A single case of severe noninfectious wound dehiscence after cavovarus reconstruction, which raises a question rather than answering it.
Relevance to CMT2C: Directly about a child with CMT2C and a possible surgical complication relevant to people with CMT2C considering foot surgery.
For this specialty: The clinical summary, including the vocal fold and respiratory features relevant before a procedure.
Relevance to CMT2C: A clinical overview written specifically about TRPV4 neuromuscular disease, with CMT2C as a named core phenotype.
Orthopedics and orthotics
The key point: the skeleton is involved beyond the usual cavus foot; the sources describe hip and spine involvement, and breathing is relevant before any long operation.
What the literature describes
Foot deformities in 73%, foot surgery in 49%, clubfoot in 45%, arthrogryposis in 33% [3].
Scoliosis in 64% of questionnaire respondents and 39% of registry records [3]. Hip dysplasia in 18% [3]; in one Australian pediatric cohort, all four children with TRPV4-related CMT had hip dysplasia on X-ray and two needed hip surgery (Tan et al., 2025).
Some TRPV4 variants also cause skeletal dysplasias, and mixed neuropathy and skeletal phenotypes exist [6](Taga et al., 2022). Short stature is reported in some families (Chen et al., 2010).
Proximal weakness (40%) and arthritic-like pain (49%) [3].
What the sources recommend
Skeletal radiographs at diagnosis and a yearly review of feet and skeleton [6]. Hip imaging in children may be worth considering (Tan et al., 2025).
Standard care as GeneReviews lists it: supportive footwear, orthotics, ankle-foot or knee-ankle-foot orthoses; daily heel cord stretching; surgery for severe cavus or contractures; orthopedic evaluation of scoliosis, with spinal fusion considered when there is pain or pulmonary compromise [6].
Custom braces in plastic or carbon fiber, and boots or high-top shoes for ankle stability [83].
Cautions
Before surgery, the breathing and the vocal folds need an anesthesia plan; see Anesthesiology.
A 2026 single case of severe noninfectious wound dehiscence after cavovarus reconstruction in TRPV4-associated CMT raises a question about healing that only more cases can answer (Elhaddad et al., 2026).
Some patients are short of breath on exertion or cannot lie flat for imaging.
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: The skeletal findings in the registry: foot deformities, scoliosis, clubfoot, arthrogryposis and hip dysplasia.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
Tan et al. · 2025 · Journal of the peripheral nervous system : JPNS
Full paperPeer-reviewed journal
For this specialty: Hip dysplasia in a large pediatric CMT cohort, including four children with TRPV4-related CMT.
Relevance to CMT2C: A general childhood CMT study with a small but striking TRPV4 result: all 4 children with TRPV4-related CMT had hip dysplasia and 2 needed surgery.
Taga et al. · 2022 · Annals of clinical and translational neurology
Full paperPeer-reviewed journal
For this specialty: Mixed neuropathy and skeletal phenotypes, and what they have in common.
Relevance to CMT2C: It is about people with TRPV4 neuropathy, including CMT2C, who also have skeletal features, and it shows in cells that a TRPV4 blocker may work differently depending on the specific change.
Cho et al. · 2012 · American journal of medical genetics. Part A
Detailed summary onlyPeer-reviewed journal
For this specialty: Three children with both a TRPV4 skeletal dysplasia and nerve involvement.
Relevance to CMT2C: It describes TRPV4 skeletal dysplasia (a bone condition caused by the same gene as CMT2C) overlapping with neuropathy, which supports seeing CMT2C as part of a wider TRPV4 spectrum.
For this specialty: How TRPV4 skeletal features changed over time in 13 patients.
Relevance to CMT2C: Mainly about TRPV4 bone growth conditions (skeletal dysplasias), with one congenital distal SMA patient and little direct CMT2C content.
For this specialty: The management list by problem: orthoses, stretching, surgery for severe cavus, contractures or scoliosis.
Relevance to CMT2C: A clinical overview written specifically about TRPV4 neuromuscular disease, with CMT2C as a named core phenotype.
Physical and occupational therapy
The key point: moderate resistance and balance training appear safe and helpful in CMT, very high-intensity training is discouraged [56], and in this subtype the hips, shoulders and breathing matter as much as the feet.
What the literature describes
Difficulty walking (79%) and with balance (79%), orthotic use (49%), at least intermittent wheelchair use (32%) [3].
Proximal leg weakness in 40% and scapular weakness, so sit-to-stand, stairs and overhead tasks are affected, not only foot clearance [3][6].
Hands: 49% struggle with buttons or zippers and 23% with eating utensils [3].
Contractures and tight heel cords, sometimes from birth [3][6].
What the sources recommend
GeneReviews: daily stretching of tight heel cords, balance work, moderate strengthening and advice on orthoses [6].
A home program the person can keep up; a systematic review of exercise in CMT (7 studies, 170 patients) found moderate resistance and balance training safe and helpful [56].
Occupational therapy for the hands: adaptive tools such as button hooks, weighted utensils and jar openers, and splints where useful [152].
Patients are often told to find a therapist who knows neuromuscular disease [65]; they may ask whether you have treated CMT before [127].
Cautions
Breathlessness during exercise or when lying down may be diaphragm weakness rather than deconditioning [288]; a referral back may be worth considering.
Very high-intensity training is discouraged in CMT [56].
For this specialty: A systematic review of exercise in CMT (7 studies, 170 patients): moderate resistance and balance training appear safe and helpful.
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: The mobility, hand and proximal-weakness figures used in this section.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
For this specialty: Muscle MRI in TRPV4-related congenital distal SMA.
Relevance to CMT2C: It includes one adult with CMT2C, but it is mostly about children with the related condition congenital distal SMA.
The patient-facing Movement guide has the self-checks and the illustrated exercises your patient may bring to you.
Audiology
The key point: hearing loss in TRPV4 disease can be an auditory neuropathy. In one child, speech perception in noise worsened over three years while the standard audiogram stayed stable (Rance et al., 2024).
What the literature describes
Partial hearing loss in 27% of registry participants [3]. Hearing loss was among the features in the first TRPV4 papers (Landouré et al., 2010).
In one family with the R269H variant, everyone with the variant developed hearing loss from the inner ear or the hearing nerve, usually noticed in mid-life (Oonk et al., 2014).
What the sources recommend
A hearing assessment at diagnosis and once a year, with rehabilitation options when loss is found [6].
Tests of speech perception in noise and auditory nerve function, not only pure-tone thresholds, may be worth considering given the case above (Rance et al., 2024).
In someone with hearing loss and an axonal neuropathy, TRPV4 is one of the genes to think of [18].
Oonk et al. · 2014 · The Annals of otology, rhinology, and laryngology
Detailed summary onlyPeer-reviewed journal
For this specialty: Variable hearing loss within one TRPV4 family, usually noticed in mid-life.
Relevance to CMT2C: It is a detailed hearing study in a TRPV4 neuromuscular family carrying R269H, which the summary notes is one of the common CMT2C mutations, though the family's own diagnosis is spinal muscular atrophy rather than CMT2C.
Lerat et al. · 2019 · Molecular genetics & genomic medicine
Full paperPeer-reviewed journal
For this specialty: Hearing loss in inherited neuropathies, with one TRPV4 case of auditory neuropathy and weak vocal cords.
Relevance to CMT2C: Mostly about other neuropathy genes, but includes one TRPV4 patient with auditory neuropathy and vocal cord paresis and a note on recorded hearing loss among five TRPV4 patients.
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: The registry figure for partial hearing loss.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
Genetics and genetic counseling
The key point: penetrance is reduced and expressivity is extreme, so the same variant can mean arthrogryposis in one relative and nothing on examination in another [6].
What the literature describes
Autosomal dominant inheritance; de novo variants and somatic mosaicism are both reported [6](Lee et al., 2025).
Reduced penetrance: a 70-year-old carrier with no detectable signs in one family (Berciano et al., 2011). How often carriers stay unaffected for life is unknown; the site tracks how each paper decided a relative was unaffected, because that is what penetrance estimates rest on.
One gene, several diagnoses: CMT2C, SPSMA and CDSMA are allelic and now described as one spectrum [6], and other TRPV4 variants cause skeletal dysplasias [6].
Variants of uncertain significance are common in TRPV4. Distinguishing pathogenic from benign variants took combined clinical, structural and cellular evidence in a 2025 study [22].
What the sources recommend
Sequence analysis detects essentially all pathogenic variants [6]. The site's TRPV4 variants page lists the well-documented neuromuscular variants and explains classifications to patients.
Genetic counseling for the family [6]. In pregnancy, a high-risk obstetrician or maternal-fetal medicine specialist is advised [6].
Reproductive options, including IVF with preimplantation genetic testing, are set out for patients on Practical tips in a deliberately non-directive way, following the ASRM's approach.
For this specialty: Reduced penetrance with the R269C variant.
Relevance to CMT2C: A detailed study of a family with a TRPV4 ankyrin-region change (Arg269Cys) that directly addresses penetrance and variability, which matter to people with CMT2C and their relatives.
For this specialty: The same variant, R269H, in several Polish families with very different severity.
Relevance to CMT2C: It is about TRPV4 neuromuscular disease caused by R269H, under labels that include CMT2C, and the summary notes that it describes Polish families.
For this specialty: De novo somatic mosaicism causing severe CMT2C.
Relevance to CMT2C: One of the two cases is a girl with severe TRPV4 neuropathy, and the idea that a TRPV4 change can be mosaic is relevant to families, but half the paper concerns a different gene (INF2).
Berth et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: Discriminating pathogenic and benign TRPV4 variants.
Relevance to CMT2C: It directly addresses how to tell disease-causing from harmless TRPV4 variants in neuropathy, which matters for anyone given an uncertain TRPV4 result, but most of the work is in lab cells rather than patients.
For this specialty: Striking variability between siblings with the same variant.
Relevance to CMT2C: It describes a family with TRPV4 axonal neuropathy and vocal cord paralysis, directly illustrating the variability and possible reduced penetrance that matter to people with CMT2C.
Thibodeau et al. · 2017 · American journal of medical genetics. Part A
Detailed summary onlyPeer-reviewed journal
For this specialty: A rare recessive pattern: two siblings who inherited a different TRPV4 variant from each parent.
Relevance to CMT2C: It describes a rare, much more severe TRPV4 condition that includes axonal neuropathy. This is relevant to how TRPV4 changes harm nerves, but it is not a description of typical CMT2C.
Pediatrics
The key point: more than half of registry participants had symptoms in the first two years of life [3]. Clubfoot, arthrogryposis, stridor or a weak cry in a baby with hypotonia can be CMT2C.
What the literature describes
Congenital presentations: clubfoot (45%), arthrogryposis (33%), and the congenital distal SMA end of the spectrum [3][6]. One family's report describes an infant who needed a breathing tube from early life while a sibling had almost no signs (Aharoni et al., 2011).
Vocal fold weakness with stridor, and respiratory weakness, in childhood as well as later [6].
Hearing: a progressive auditory neuropathy was documented in one child despite a stable audiogram (Rance et al., 2024).
What the sources recommend
The GeneReviews baseline (laryngoscopy, lung function, sleep study, hearing, skeletal radiographs) and yearly review, with height and weight at every visit [6].
Early physical therapy for contractures and heel cords [6], and genetic counseling for the family [6].
The Johns Hopkins natural history study enrolls from age 3 [101].
Cautions
Respiratory infections, anesthesia and oxygen carry the same cautions as in adults; see Pulmonology and Anesthesiology.
Severity in a child does not predict the course: one newborn who was very ill improved over the following years while his father stayed stable for two decades (Vill et al., 2015).
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: Age of onset and the congenital features in the registry.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
Tan et al. · 2025 · Journal of the peripheral nervous system : JPNS
Full paperPeer-reviewed journal
For this specialty: Hip dysplasia in children with CMT, including four with TRPV4-related CMT.
Relevance to CMT2C: A general childhood CMT study with a small but striking TRPV4 result: all 4 children with TRPV4-related CMT had hip dysplasia and 2 needed surgery.
For this specialty: Siblings with the same variant, one needing a breathing tube from early life and one almost unaffected.
Relevance to CMT2C: It describes a family with TRPV4 axonal neuropathy and vocal cord paralysis, directly illustrating the variability and possible reduced penetrance that matter to people with CMT2C.
For this specialty: A newborn who was very ill and improved over the following years, while his father stayed stable for two decades.
Relevance to CMT2C: It gives rare long-term follow-up of TRPV4 neuromuscular disease with R269C, including late sensory nerve involvement, though the family's diagnosis is scapuloperoneal syndrome rather than CMT2C.
Fleming et al. · 2016 · Neuromuscular disorders : NMD
Abstract onlyPeer-reviewed journal
For this specialty: Congenital spinal muscular atrophy with pain in a child with a TRPV4 variant.
Relevance to CMT2C: It describes pain and sensory symptoms in a person with the TRPV4 change Arg269His (c.806G>A), and makes points about diagnosis relevant to TRPV4 neuromuscular disease generally.
Taga et al. · 2022 · Annals of clinical and translational neurology
Full paperPeer-reviewed journal
For this specialty: Mixed neuropathy and skeletal phenotypes, which tended to start early.
Relevance to CMT2C: It is about people with TRPV4 neuropathy, including CMT2C, who also have skeletal features, and it shows in cells that a TRPV4 blocker may work differently depending on the specific change.
Primary care and emergency departments
The key point: chest infections carry extra risk when the cough is too weak to clear secretions; the sources caution that oxygen alone can hide rising carbon dioxide and that CPAP does not treat weak breathing muscles [288][153][307].
In an emergency
The patient usually knows about their breathing-muscle weakness, nocturnal ventilation and vocal fold weakness, so it is worth asking [3].
Carbon dioxide, not only saturation, is the measurement the sources ask for [126]. If oxygen is needed, the sources advise giving it with ventilatory support rather than alone [153].
Noisy breathing, a sudden change in voice or swallowing, or increasing breathlessness need urgent assessment [6].
Clearing secretions: air stacking or mechanical insufflation-exsufflation if available [288].
In the office
The yearly checks in GeneReviews are voice box, breathing, sleep, hearing, feet and skeleton [6]. The care team guide on this site is the patient's checklist for them.
Sleep is worth a question: orthopnea, unrefreshing sleep and morning headache are early signs of nocturnal hypoventilation [288][289].
Prescribing: vincristine and paclitaxel are the two drugs to avoid; other drugs have no convincing evidence of harm, and effective treatment should not be withheld [35][36].
Weight, diabetes and respiratory infections are the things GeneReviews says to avoid or treat early [6].
Bladder symptoms (45% difficulty urinating, 26% incontinence) and pain (49% arthritic-like) are common and rarely asked about [3]. So is low mood; the site has a page for both.
Referral to a neuromuscular neurologist or a CMT Center of Excellence is the usual next step [85].
Kosmanopoulos et al. · 2025 · Brain : a journal of neurology
Full paperPeer-reviewed journal
For this specialty: How common each problem is, including the bladder and pain figures that are easy to miss.
Relevance to CMT2C: The largest study so far of people with TRPV4 neuromuscular disease, including CMT2C, describing symptoms and change over time in ways patients can relate to.
For this specialty: A case with isolated sweating (sudomotor) dysfunction, one of the autonomic features rarely asked about.
Relevance to CMT2C: It describes a person with CMT2C and a problem, poor sweating with overheating, that the summary notes is not on the usual CMT2C symptom lists.
Natural history studies. Johns Hopkins, NCT05600764: ages 3 to 80 with a TRPV4 variant, United States and Canada, one visit a year for six years, travel reimbursed [101].INC 6601: any CMT type, 21 sites in the US, Canada, the UK, Italy and Australia [52]. The 2025 registry paper was built from INC data [3].
Treatment pipeline.STAR-0871 (previously ABS-0871) is an oral TRPV4 inhibitor with FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations; a Phase 1b study in people with CMT2C is planned for 2027 [318][319]. The Trials and research page follows every candidate.
The literature.Papers explained analyzes 106 papers in detail and lists 271 in all, each labeled by how it was read and what its evidence rests on. How the papers were analyzed explains the method.
Corrections. If something on this page is wrong or out of date, please tell me: cmt2cinfo@gmail.com. Clinicians' corrections have already shaped this site, and I will credit you if you wish.
This page brings together published expert sources for education; it is not medical advice or a clinical guideline. Every statement is referenced to the numbered sources. Last reviewed October 2026.